Madison El-Saadi

Madison El-Saadi, Ph.D., is a healthcare equity research analyst at B. Riley Securities, Inc. He joined the B. Riley healthcare team in 2022, where his research coverage includes smid-cap biotech companies within the neuroscience, rare disease, vaccine, and RNA-based therapeutic sectors. Prior to B. Riley, Madison was in equity research at Raymond James, focusing on neuroscience and rare disease therapeutic areas.

Before joining Wall Street, he was a Fellow at the Texas Institute for Restorative Neurotechnologies (TIRN), where he developed innovative therapies for neurodevelopmental and neurodegenerative disorders. Madison earned his Ph.D. in neuropharmacology from Louisiana State University School of Graduate Studies and completed postdoctoral work at McGovern Medical School and the University of Texas Health Science Center at Houston.